• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Predicting Pregnancy Loss Due to Subchorionic Hematoma

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • There have been different reporting/grading systems for the severity of subchorionic hematoma (SCH)
    • Subjective grading as small, moderate, or large
    • Volume measurement
    • Estimation of hematoma size as a fraction of gestational sac
    • Estimated fraction of the gestational sac surrounded by hematoma
  • No previous studies have assessed grading systems and risk for pregnancy loss
  • Heller et al. (Journal of Ultrasound in Medicine, 2018) determined which SCH grading system in first trimester correlates best with miscarriage

METHODS:

  • Retrospective data review
    • First trimester live singleton pregnancies with SCH
    • Between 6-11 weeks gestational age
  • First-trimester outcome was categorized as
    • Live: Ultrasound > 14 weeks with an FH or live birth documented in the medical record
    • Demise: Ultrasound showing pregnancy loss <14 weeks or miscarriage documented in the medical record
  • SCH were categorized as
    • Subjective: SCH is graded as small, moderate or large
    • Subjective: SCH size based on fraction of gestational sac size
      • ≤10% | 11-25% | 26-50%, >50%
    • Subjective: SCH sized based on fraction of the gestational sac surrounded by hematoma using the same four percentage categories above
    • Volume: Measurement of 3 orthogonal dimensions of the SCH
  • Primary outcome
    • Determine superior SCH size estimate approach for predicting pregnancy outcome
  • Secondary outcome
    • Assess whether gestational age at the time of SCH diagnosis affects pregnancy outcome

RESULTS:

  • Total 434 sonograms met study inclusion criteria
  • Overall rate of first-trimester pregnancy failure with SCH was 12.0%
  • Rate of demise was higher when gestational age at the time of SCH diagnosis was lower (P < .001)
    • ≤7 weeks: Rate of demise was 19.6%
    • >7 to 8 weeks: Rate of demise was 14.6%
    • >8 weeks: Rate of demise was 3.6%
  • Vaginal bleeding and use of ART did not impact the rate of miscarriage
  • The size of the hematoma estimated as a fraction of gestational sac size significantly correlated with first trimester pregnancy loss (P <0.001)
    • 6-11 weeks (all GAs): AUC 0.660
    • ≤8 weeks: AUC 0.613
  • Risk of fetal demise based on hematoma size as fraction of gestational sac size (diagnosed 6-11 wks)
    • SCH <10% of GS size: 5.8%
    • SCH 10-25% of GS size: 8.9%
    • SCH 26-50% of GS size: 10.8%
    • SCH >50% of GS size: 23.3%
  • There was no statistical significance between first trimester outcome and the other 2 subjective grading methods
  • The least reliable results were obtained when volume (3 measurements) was used due to irregular shape of most SCHs

CONCLUSION:

  • The use of SCH vs gestational sac size as a ratio measurement correlated with pregnancy failure in the first trimester
  • Volume-based measurements were not accurate
  • The earlier in pregnancy an SCH is detected, the higher the rate of subsequent pregnancy loss

Learn More – Primary Sources:

Subchorionic Hematoma: Correlation of Grading Techniques With First‐Trimester Pregnancy Outcome

Get Guideline Notifications direct to your phone with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite

< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Early Pregnancy Loss: How to Make the Ultrasound Diagnosis
Managing Early Pregnancy Loss

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site